Post Transplant Donor Lymphocyte Infusion

Phase 2 Terminated 57 enrolled Masonic Cancer Center, University of Minnesota

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test the hypothesis that a pre-infusion preparative regimen of cyclophosphamide and fludarabine will improve the effectiveness of DLI in patients with blood cancers.

Timeline

Start: 2004-01
Primary completion: 2017-11-21
Completion: 2018-12-24

Outcome

Outcome not reported

Stopped (Enrollment): “Accrual Goal Met”

Publications

Miller JS, Weisdorf DJ, Burns LJ, Slungaard A, Wagner JE, Verneris MR, Cooley S, Wangen R, Fautsch SK, Nicklow R, Defor T, Blazar BR. Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood. 2007 Oct 1;110(7):2761-3. doi: 10.1182/blood-2007-05-090340. Epub 2007 Jun 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	60 mg/kg	Intravenous
Subject	Fludarabine	Small molecule	25 mg/m2	Intravenous